{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:48:09Z","timestamp":1783648089263,"version":"3.55.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The utility of \u03b2-emitter <jats:sup>177<\/jats:sup>Lu-DOTATATE in patients of neuroendocrine tumors (NETs) with widespread skeletal metastases is limited by its relatively modest response rates and a significant concern for hematotoxicity. In such situations, targeted \u03b1 therapy with <jats:sup>225<\/jats:sup>Ac-DOTATATE can be potentially beneficial. In this report, a 46-year-old man with rectal NET and extensive skeletal metastases was treated upfront with 6 cycles of <jats:sup>225<\/jats:sup>Ac-DOTATATE at 8 weeks\u2019 intervals. The patient showed excellent symptomatic, biochemical, and radiological response with no grade 3\/4 adverse events. The first-line use of <jats:sup>225<\/jats:sup>Ac-DOTATATE, therefore, presents a novel strategy for metastatic NETs with high skeletal disease burden.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003823","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:54Z","timestamp":1626825654000},"page":"e156-e157","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Alpha Before Beta"],"prefix":"10.1097","volume":"47","author":[{"given":"Swayamjeet","family":"Satapathy","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan Krushna","family":"Das","sequence":"additional","affiliation":[{"name":"Medical Oncology, Regional Cancer Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwin Joseph","family":"Kavanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","year":"2017","journal-title":"Theranostics"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.3390\/molecules24234314","article-title":"Development of targeted alpha particle therapy for solid tumors","volume":"24","year":"2019","journal-title":"Molecules"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"18489","DOI":"10.1038\/s41598-019-54884-7","article-title":"Radiobiological effects of the alpha emitter Ra-223 on tumor cells","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2967\/jnumed.117.204651","article-title":"\u03b1-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 2","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-DOTATATE for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1097\/RLU.0000000000003170","article-title":"Peptide receptor radionuclide therapy as first-line systemic treatment in advanced inoperable\/metastatic neuroendocrine tumors","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RLU.0000000000002915","article-title":"Peptide receptor radionuclide therapy using 225Ac-DOTATOC achieves partial remission in a patient with progressive neuroendocrine liver metastases after repeated \u03b2-emitter peptide receptor radionuclide therapy","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:07:45Z","timestamp":1750536465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003823"}},"subtitle":["Exceptional Response to First-Line 225Ac-DOTATATE in a Patient of Metastatic Neuroendocrine Tumor With Extensive Skeletal Involvement"],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003823","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,20]]}}}